Biofrontera (BFRI) investor relations material

Executive summary

• Achieved record annual revenues of $41.7 million in 2025, up 12% year-over-year, with Q4 revenues at $17.1 million, a 36% increase from the prior year.

• Q4 2025 was highly profitable, with net income of $5.6 million and Adjusted EBITDA of $4.9 million, driven by a new asset purchase agreement and improved cost structure.

• Transitioned to full ownership of U.S. Ameluz and RhodoLED assets, reducing earnout rates and gaining full regulatory and manufacturing control.

• Advanced clinical pipeline with positive Phase 2b and Phase 3 results, FDA acceptance of sNDA for Ameluz PDT, and plans for further filings.

• Divested Xepi license for $3 million upfront, with potential for $7 million in milestones, and raised $11 million via Series C preferred stock.

Financial highlights

• Q4 2025 revenues reached $17.1 million, up from $12.6 million in Q4 2024; gross profit margin improved from 58% to 82%.

• Full-year 2025 revenues were $41.7 million, up from $37.3 million in 2024; gross profit margin rose from 50% to 74%.

• Q4 net income was $5.6 million, a $7 million improvement year-over-year; full-year net loss narrowed to $10.5 million from $17.8 million.

• Adjusted EBITDA for Q4 was $4.9 million (29% margin); full-year Adjusted EBITDA improved to -$10.6 million from -$15.3 million.

• Cash and equivalents at year-end were $6.4 million, up from $5.9 million.

Outlook and guidance

• Gross profit margins expected to be 80%-85% throughout 2026, reflecting the full benefit of the new cost structure.

• Anticipates cash flow breakeven and sustained profitability as operational improvements and lower costs take full effect in 2026.

• PDUFA date for SBCC indication set for September 28, 2026; plans to file sNDA for AK on extremities in Q3 2026.